Open access
Open access
Powered by Google Translator Translator

M-A: In patients with acute coronary syndrome, a guided approach (i.e., platelet function or genetic testing) to P2Y12 inhibiting therapy may reduce major adverse cardiovascular events without increased risk of bleeding.

21 Jan, 2022 | 09:33h | UTC

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials – European Heart Journal (link to abstract – $ for full-text)

Commentary: Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis – TCTMD

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.